Economic analysis of bevacizumab, cetuximab, and panitumumab with fluoropyrimidine-based chemotherapy in the first-line treatment of KRAS wild-type metastatic colorectal cancer (mCRC)

By Lawrence Donna   Maschio Michael   Leahy Kevin J.   Yunger Simon   Easaw Jacob C.   Weinstein Milton C.  

Journal of Medical Economics, Vol. 16, Iss. 12, 2013-12 ,pp. : 1387-1398

Informa Healthcare

Access to resources Recommend Favorite

Bevacizumab plus Oxaliplatin-Based Regimens for the Treatment of Colorectal Cancer

By  

Oncology Research and Treatment, Vol. 32, Iss. 7, 2009-06 ,pp. : 431-439

Karger

Access to resources Recommend Favorite

Bevacizumab plus Irinotecan-Based Regimens in the Treatment of Metastatic Colorectal Cancer

By  

Oncology, Vol. 79, Iss. 1-2, 2010-11 ,pp. : 118-128

Karger

Access to resources Recommend Favorite

Bevacizumab plus Irinotecan-, Fluorouracil-, and Leucovorin-Based Chemotherapy with Concomitant HAART in an HIV-Positive Patient with Metastatic Colorectal Cancer

By  

Oncology Research and Treatment, Vol. 31, Iss. 7, 2008-06 ,pp. : 394-397

Karger

Access to resources Recommend Favorite

An Open-Label Safety Study of First-Line Bevacizumab in Combination with Standard Chemotherapy in Chinese Patients with Metastatic Colorectal Cancer Treated in an Expanded Access Program in Taiwan

By  

Oncology, Vol. 84, Iss. 5, 2013-03 ,pp. : 299-304

Karger

Access to resources Recommend Favorite